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Abstract: Periodontal disease, periodontitis as well as the preceding gingivitis, has been associated
with both obesity and diabetes. Studies have shown that diet changes can lead to a lower incidence of
such inflammation. The aim of the present case series over four weeks was to study the effects
on medical and dental conditions in patients with type 2 diabetes of the consumption of the
Okinawan-based Nordic Diet (OBND®). Medical and dental examinations were performed to
estimate the general health and gingivitis/periodontitis. Serum cytokine levels were assessed using
Luminex technology. Eight of ten study participants completed the study. All participants lost weight
(p = 0.012). Six out of seven that were treated with insulin could reduce their insulin intake after
two weeks with OBND®. The reduction was about 16 units which corresponds to a 34% relative
reduction compared to the starting point (range 15–63%). Fasting blood glucose values fell (p = 0.035).
Hemoglobin A1c (HbA1c) (p = 0.01), triglycerides (p = 0.05), and low-density lipoprotein (LDL)
(p = 0.05) were also reduced. Bleeding on probing changed from ~28% before any dietary changes to
~13% after two weeks with OBND® (p = 0.01). The reduction in gingival bleeding was as substantial
as might be expected from one session of professional tooth cleaning. Markers of inflammation were
also reduced. The OBND® thus showed significant promise in alleviating the impact of diabetes on
dental as well as general health.
Keywords: diet; oral health; metabolic disorder; cytokines; bleeding on probing; clinical study
1. Introduction
Obesity poses a major public health challenge worldwide. In the Swedish adult population,
approximately 35% is overweight, and with almost 15% defined as being obese [1]. The obesity
rate is somewhat higher in southern Sweden [2]. Type 2 diabetes (T2D) is associated with sustained
obesity with several health complications. One of the signal complications of both obesity and diabetes
is chronic periodontal disease [3]. Periodontitis is a chronic inflammatory disease of the mouth
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involving the gum tissues (gingiva), the teeth, and the supporting bone. Periodontitis is clinically
defined as loss of connective tissue attachment to the teeth, accompanied by alveolar bone loss.
Periodontal tissue destruction is caused by host responses to the development of a complex bacterial
biofilm [4]. Periodontal infections trigger the release of pro-inflammatory cytokines both at the site of
the infection and through the endothelial cell system [5]. Gingivitis is inflammation of the gums and it
is generally perceived that periodontitis is preceded by gingivitis, but the etiology of the transition
from gingivitis to periodontitis remains unknown.
In the general population, periodontitis is highly prevalent [6]. The Centers for Disease Control
and Prevention (CDC, Atlanta, GA, USA) have identified that one out of every two American adults
aged 30 and over has periodontitis, and that the prevalence increases to 70% in older adults [6]. In a
global review on severe periodontitis, the prevalence in USA (high income) was comparable with
that in Western Europe with a prevalence of 7.2% and 9.8%, respectively. The highest numbers were
found in Eastern Africa and South America with prevalence rates approaching 20%. In contrast,
the lowest prevalence was found in Oceania with only 4% affected [7]. Recent data have identified
that dysregulation of biomarkers, with increased glucose, dyslipidemia and hepatic damage can
be demonstrated through comorbidity of obesity and periodontitis with effects on both systemic
inflammatory and metabolic conditions [8]. Insulin resistance has been associated with both obesity
and periodontitis [9,10]. Obesity-induced insulin resistance and vascular gingival inflammation has
also been demonstrated [11]. Besides the metabolic syndrome, other variables must be considered
when evaluating periodontal parameters, as results could be affected. Professional and domiciliary
oral hygiene protocols [12], the presence of orthodontic appliances [13] or the presence of other chronic
diseases such as for example chronic obstructive pulmonary disease [14] could be examples of such
confounding factors.
Several studies have reported that chronic periodontitis is prevalent in patients with T2D [8,15,16].
The Swedish National Board of Health and Welfare (2015) states in its guidelines for diabetes care that
healthcare professionals should refer patients for dental care if patients have ongoing inflammation of
the gums (gingivitis or periodontitis). The evidence on the efficacy of routine non-surgical periodontal
therapy in individuals with diabetes is contradictory. Some studies have suggested that non-surgical
periodontal therapy may be associated with a reduction in hemoglobin A1c (HbA1c) level [17,18].
Other studies have failed to show that non-surgical periodontal therapy or periodontal disease severity
were associated with significant changes in serum biomarkers [19,20]. In a Cochrane report, the authors
concluded that there is low quality evidence that the treatment of periodontal disease by non-surgical
therapy does improve glycemic control in people with diabetes [21].
In poorly controlled T2D, the presence of pro-inflammatory cytokines and chemokines in serum
may partially explain the greater susceptibility of T2D patients to periodontal breakdown [22,23].
Fundamental dietary changes may achieve sustainable control of inflammation. The medical benefits
of excellent nutrition are well documented and can in many cases result in improved health. Studies
have shown that changes in diet can reduce inflammation [24,25], including the control of gingival
inflammation [26]. Recent data suggest that a diet low in carbohydrates, rich in omega-3 fatty acids,
fibers and vitamins C and D, may significantly reduce gingival and periodontal inflammation [27].
Inhabitants of the Japanese island of Okinawa maintain a traditional low-stress lifestyle,
which includes a natural non-refined diet resulting in one of the highest longevity in the world [28].
The typical diet includes a high intake of grains, vegetables, legumes, root vegetables, fish, poultry,
fruit and nuts. A modified Okinawan-based Nordic diet (OBND®) based on the principle content
of the traditional diet on Okinawa has been developed by the Igelösa Life Science AB, Sweden.
The diet restricts the intake of sugar, red meat, and dairy products. Data from a recent study included
individuals with T2D and used the principles of such a diet; this led to the remarkable finding that
several individuals no longer required insulin therapy and others could reduce the daily intake of
insulin [29].
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The aim of the present pilot study was to study the impact of intake of a specific healthy
diet on markers of general and oral health, and markers of inflammation in individuals with T2D.
The study more specifically aimed at testing the “proof of principle”, that is, whether adherence to
OBND®, founded on the recommendations of the Swedish National Food Agency, would result in
reductions/changes of clinical and medical/dental parameters of value for the treatment of T2D and
gingivitis/periodontitis. Moreover, the study aimed at determining adequate statistical power to be
used in a future, case control study.
2. Results
Before starting the study diet, one examined individual was admitted to hospital unrelated to
study procedures. In addition, one study participant was prescribed antibiotics for a dental procedure
and was therefore excluded from the analyses. Thus, eight of the ten enrolled study participants
(two females, and six males) diagnosed with T2D completed the study. The mean age of the study
group was 59.0 years (S.D. ± 8.1). Descriptive statistics including data on serum variables and general
health parameters are presented (Tables 1 and 2). During the study, all study participants lost weight
(p = 0.01). Seven of them were under daily treatment with insulin. After two weeks with OBND®,
6/7 individuals reduced their insulin intake (Figure 1). The mean reduction was approximately 16
units which corresponds to 34% relative reduction compared to the starting point (range 15–63%;
p = 0.05). Fasting blood glucose values fell (p = 0.05). HbA1c (Figure 2; p = 0.01), triglycerides (p = 0.05),
and low-density lipoprotein (LDL) levels (p = 0.05) were also reduced.
Table 1. Baseline data of the enrolled patients.
Patient
Code
Age
(Years) Gender
Diabetes
Duration (Years) Tobacco Complications Medication
1 56 male 6 Quit 2010 Hyperlipidemia, hypertension,myocardial infarction Metformin
2 72 male 30 Never Hyperlipidemia, hypertension,retinopathy
Metformin, insulin,
Glucagon-like
peptide-1
3 51 female 19 Never
Hypertension, sleep apnea
syndrome, acromegaly,
hyperthyroidism
Levaxin, Genotropin,
insulin
4 63 male 24 Quit 1991 Hyperlipidemia, hypertension,retinopathy, nephropathy
Metformin, insulin,
Glucagon-like
peptide-1
5 65 male 9 Quit 2006 Hyperlipidemia, hypertension,cerebrovascular insult Insulin
7 63 female 16 Quit 2015 Hyperlipidemia, hypertension
Metformin, insulin,
Glucagon-like
peptide-1
9 48 male 6 Quit 1990 Hyperlipidemia, hypertension,sleep apnea syndrome Metformin, insulin
10 54 male 10 Quit 2009 Hypertension, retinopathy,nephropathy, hepatitis C Insulin
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Table 2. Mean levels and standard deviations (S.D.) of medical values in individuals with type 2
diabetes (T2D) at 2 weeks (before intake of study diet), and after two weeks with the study diet.
Medical Data
Mean S.D. Mean S.D.
Statistical
SignificanceBefore Study Diet
(Week 2; n = 8)
At Study Endpoint
(Week 4; n = 8)
Weight (kg) 95.1 11.6 92.3 11.1 p = 0.01
Body mass index (BMI; kg/m2) 31.8 3.4 30.8 3.4 p = 0.01
Waist circumference (cm) 110.6 5.9 107.6 6.6 p = 0.01
Systolic blood pressure (mm Hg) 143.5 11.6 138.3 14.9 p = 0.26
Diastolic blood pressure (mm Hg) 79.8 8.8 77.8 6.3 p = 0.61
Fasting glucose (mmol/L) 10.4 2.7 6.8 2.2 p = 0.05
Hemoglobin A1c (HbA1c; mmol/mol) 68.4 16.1 62.5 13.9 p = 0.01
Triglycerides (mmol/L) 2.8 1.9 1.5 0.8 p = 0.05
Low-density lipoprotein (LDL; mmol/L) 2.5 0.9 1.8 0.8 p = 0.05
Bleeding on probing (BOP; %) 28.5 8.7 13.3 7.0 p = 0.01
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two weeks with the Okinawan-based Nordic diet.
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2.1. Analysis of Gingivitis and Periodontitis
At baseline, a diagnosis of gingivitis was identified in 75% of the individuals. Independent t-test
failed to demonstrate changes in bleeding on probing (BOP) between baseline and 2 weeks (before
intake of study diet). Between week 2 and week 4 the reduction in BOP was significant, from ~28%
before any dietary changes to ~13% after two weeks with the OBND® (mean diff: 15.2%, standard
error (S.E.) diff: 3.9, 95% confidence interval (CI): 23.7, 6.7, p = 0.002) (Table 2, Figure 3).
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Figure 3. Bar chart diagram illustrating mean changes in bleeding on probing (BOP; %) at different
time points of the study (baseline [mean ± S.D.; 27.1 ± 10.0], before study diet [28.5 ± 8.7] and at study
endpoint [13.3 ± 7.0]).
Measurements of panoramic X-rays were performed by a periodontist (RP) without knowledge of
medical conditions, age or gender for the study participants. Alveolar bone loss was measured on the
panoramic radiographs using a computer software for studies of metric changes (Osiris Pixmeo SARL,
Bernex, Switzerland). None of the study individuals showed radiographic evidence of alveolar bone
loss suggesting a diagnosis of periodontitis.
2.2. Analysis of Gingivitis and Diabetes
All participants reduced their HbA1c levels (p = 0.05). Between week 2 and week 4 the reduction
in HbA1c was significant, from 68.5 mmol/mol before any dietary changes to 62.5 mmol/mol after
two weeks with the OBND® (Table 2).
The correlation between BOP and HbA1c at study endpoint are illustrated in a scatterplot diagram
(Figure 4).
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2.3. Analysis of High-Sensitivity C-Reactive Protein and Serum Cytokines
A reduction in high-sensitivity C-reactive protein (hs-CRP) was identified in all individuals but
one. Changes in pro-inflammatory cytokines were analyzed in individuals with a reduction of hs-CRP
(Table 3). A 10% reduction was identified in five cytokines (interleukin (IL)12, IL13, interferon-inducible
protein-10 (IP10, monocyte chemo-attractant protein-1 (MCP)1, and vascular endothelial growth factor
(VEGF) and with a 20% only three cytokines remained (IL12, IP10, and MCP1). 6/7 individuals showed
a reduction in hs-CRP and 5/7 a reduction in MCP1. The other inflammatory markers did not change
to the same extent.
Table 3. Median and 25th and 75th percentile of high sensitivity C-reactive protein (hs-CRP) and
pro-inflammatory cytokines in individuals with type 2 diabetes at 2 weeks (before intake of study diet),
and after two weeks with the study diet. Presentation of cases with either 10% or 20% reduction of
pro-inflammatory cytokines.
Variable Cases with Reduction
Before Study Diet (Week 2) At Study Endpoint (Week 4)
Significance
Median 25% 75% Median 25% 75%
≥10% reduction
hs-CRP (mg/L) 7 2.3 1.4 2.7 1.6 0.6 2.1 p = 0.05
IL12 (pg/mL) 2 54.8 27.1 64.0 37.7 27.4 61.1 NS
IL13 (pg/mL) 5 5.3 4.9 5.3 4.5 4.1 5.3 NS
IP10 (pg/mL) 3 482.3 327.2 776.0 372.6 279.6 915.0 NS
MCP1 (pg/mL) 5 8.2 2.6 10.3 2.1 0.0 9.0 p = 0.05
VEGF (pg/mL) 3 182.4 92.8 230.9 157.9 106.3 174.0 NS
≥20% reduction
hs-CRP (mg/L) 6 2.3 1.4 2.7 1.6 0.6 2.1 p = 0.05
IL12 (pg/mL) 2 54.8 27.1 64.0 37.7 27.4 61.1 NS
IP10 (pg/mL) 2 482.3 327.2 776.0 372.6 279.6 915.0 NS
MCP1 (pg/mL) 5 8.2 2.6 10.3 2.1 0.0 9.0 p = 0.05
3. Discussion
In this 2-week dietary intervention with the Okinawan-based Nordic diet (OBND®), significant
reductions in weight, body mass index and waist circumference were identified despite the limited
number of participants and short intervention period. It should be noted that a clinical reduction in
HbA1c levels of 5% is considered good and a satisfactory level for a new pharmaceutical [30,31]. All the
participating individuals except one, reduced their HbA1c levels by more than 5%. Furthermore,
beneficial effects in glucose and lipid metabolic homeostasis were identified, resulting in reduced
insulin intake. This is in line with the previous 12-week study with the OBND® [29]. While any
restricted and nutritious diet may have positive benefits, several features make the OBND® unique;
(I) the health benefits on clinical parameters were extremely rapid, that is, within two weeks; and (II)
the diet has a proven positive impact on the clinical progress of an otherwise debilitating condition
such as diabetes. The diet was also well accepted by the study participants. The fact that all participants
showed evidence of a substantial comorbidity with metabolic syndrome and diabetic complications
should also be considered. Since the inflammatory response is driven by several pro-inflammatory
diseases besides diabetes per se the effect of the OBND® diet is probably reduced in this cohort and
may be underestimated.
There are limited data on cost-effectiveness through administration of a well-balanced nutritional
diet aimed at individuals with diabetes in relation to insulin requirements, physician care,
dental conditions, and overall signs of inflammation. Obesity and T2D are driven by energy-dense
diets and sedentary lifestyles [32]. Low-carbohydrate diet has been associated with normal body
weight [33]. Okinawa is a Japanese island where the people maintain traditional lifestyle, natural
non-refined diet along with low levels of stress, and they are ranked as number one in the world for
healthy longevity. The Okinawa diet is characterized by (I) reduced intake of calories; (II) rich sources
of antioxidants, and minerals including calcium, iron, potassium; and zinc (III) reduced intake of fat,
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and sugar; (IV) richness of vegetarian and seafood components. Caloric restriction and traditional
Okinawan functional foods may partly explain the extended health and lifespan of the Okinawans [34].
Recent data suggest, however, that life expectancy in Japan is now declining [35]. This may in part
be explained by dietary changes and adjustments to similar dietary habits as in other parts of Japan,
and worldwide.
A healthy Nordic diet includes intake of fatty fish, low-fat dairy, whole grain cereals such as oats
and barley, berries, root vegetables, rapeseed oil, nuts and legumes [36]. Such a diet improves blood
lipid profile, insulin sensitivity, and lowers blood pressure and body weight in hyper-cholesterolemic
individuals and is associated with decreased morbidity and mortality. An Okinawan-based Nordic
diet with moderately low carbohydrate content and high fiber, unsaturated fat, and protein contents
renders increased satiety, reduced sweet craving and improved insulin levels, reduction in blood
glucose, improvements in body weight, body mass index, total cholesterol, low-density lipoprotein
cholesterol, lower systolic and diastolic blood pressure [29]. The health effects are mediated both by
certain components in the diet such as fibers, unsaturated fat and antioxidants in vegetables and fruits
and by the combined effect of all these factors together.
Diabetes is a risk factor for increased prevalence of gingivitis and periodontitis approaching
almost 70% and 25%, respectively [37]. A survey of periodontal conditions of young adults in Sweden
identified that 44% of young adults in Sweden were diagnosed with gingivitis [38]. A diet rich in
fruits and vegetables has been associated with better periodontal health as it may reduce gingival
bleeding [26] and pocket depths [39]. Although the participating individuals already had relatively
good oral hygiene as reflected by gingival inflammation with bleeding on probing approaching
27–28%, this was reduced by more than half after only two weeks of dietary change. In addition to
conventional care, that include oral bacteria control [40], in office ultrasonic instrumentation [41] and
home care protocols [42] also diet has to be considered a crucial factor for the maintenance of healthy
oral conditions. Since periodontitis is an inflammatory condition associated with insulin resistance the
fast and vast impact on dental health by the OBND® this kind of intervention should be regarded as
an important facet in the treatment regimen of T2D.
Diabetes and obesity is accompanied by increases in pro-inflammatory cytokine levels.
Obesity affects both the innate and the adaptive immune system, which cause negative health impacts
on the circulatory system, leading to increased risk of T2D and insulin resistance. This predisposes to
higher mortality and morbidity. There is also a link between obesity, insulin resistance and increased
adipose tissue inflammation. The present study indicated that predominantly markers of the innate
and cell mediated immunity were influenced by the dietary intervention. Adipose tissue produces
pro-inflammatory cytokines such as MCP1 by recruiting macrophages into fat [43], thus functioning
as a risk marker of atherosclerosis. MCP1 is present at increased concentrations in individuals with
T2D [44]. A recently completed study of diet and cytokines identified that a Mediterranean diet resulted
in significant reductions of pro-inflammatory biomarkers and MCP1 and macrophage inflammatory
protein 1 beta (MIP1β) concentrations in atheroma plaque development as compared to a low-fat
diet [45]. Analysis of inflammatory parameters in participating individuals identified that serum
concentrations of MCP1 were higher at baseline than after two weeks with the OBND®. The dietary
change thus provides a change in immune status after only two weeks.
This work is essentially a pilot study with limited data over a shorter time span, although the
changes identified herein are clinically encouraging. Another limitation is that the study design is a
case series where the participants serve as their own controls though a cross-over design, which does
increase the risk for examiner bias during the dental clinical examinations. The short-term duration
of the present study is another limitation not allowing to control for compliance and interests in
continuing with the OBND®. All meals were provided and delivered to the participants with
restrictions on supplemental snack intakes. Interviews were made with participants confirming
compliance with the diet intake. Furthermore, a family member also received the diet to support
compliance. The major limitation of the present pilot study is the lack of control group and lack of
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long term data. However further studies are needed to confirm the results of this preliminary report
with randomized controlled trials.
Based on the above reported studies and available data on blood sugar and lipid values, we met
one of the study aims identifying that at least 18 individuals in each group would provide adequate
statistical power (α = 0.05, β = 0.85).
The study clearly identified clinically relevant changes in insulin dosage needs and reduced
gingival inflammation. In fact, the reduction of gingival inflammation matches improvements
following professional dental care. Results from the study show that the potential for dietary-mediated
improvement in dental health in vulnerable populations is extremely significant, reducing disease
burden and improving quality of life. The impact of this diet in reducing obesity, improving diabetic
control, cardiac and dental health, will also have a significant effect in morbidity, and longer life
expectancy. Perhaps, dietary changes and implementation of a diet based on the principles of
OBND® have potential to be a highly efficient approach to making general improvements in human
health world-wide. There is, therefore, a need to strengthen the case for the direct impact of dietary
modulation for diabetes prevention and care as well as the management of periodontal conditions.
In the next steps prospective randomized controlled trials with a health promoting diet as well
as studies aiming at understanding the mechanisms for health benefits on a molecular level are
highly warranted.
4. Patients and Methods
In compliance with the Declaration of Helsinki, the Regional Ethics Committee in Lund, Sweden,
approved the study (Institutional Review Board approval No. 2016/582, 13 September 2016). The study
has also been registered (ClinTrials: NCT02916589). All participating individuals signed written
informed consent.
The following inclusion criteria for participation were: (I) a medically confirmed diagnosis of T2D
in the past 5 or more years; (II) currently 18 years of age or older; (III) having ≥20 remaining teeth,
and (IV) from logistic perspectives that study participants were living within a confined area allowing
convenient distribution of the daily diets. The exclusion criteria were: (I) treatment with antibiotics
during the preceding three months; or (II) no changes in other prescribed medications during the
study. Based on information from medical records, potential study participants were identified by an
endocrinologist (HH). Identification of potential study individuals were based on the criteria above
and elevated serum HbA1c values.
A total of 12 individuals with T2D were asked to participate in the study. While 2 individuals
declined participation due to the amount of time necessary to participate and other logistical issues,
10 individuals were included in the study. As the present report is a pilot study, no sample size has
been calculated and the number of patients enrolled was depending on Department flow of works.
Medical and dental routine examination procedures were performed two weeks before the change in
dietary conditions, immediately before the start of study diet, and after two weeks (study endpoint).
4.1. Study Diet
The Okinawan-based Nordic diet was prepared following the principles of the Okinawa diet
modified by principles of healthy food in Scandinavia at the kitchen of Igelösa Life Science AB, Lund,
Sweden. The study individuals were provided three meals/day including breakfast, lunch, and dinner
(Table 4). The diet also included two snacks between meals consisting of a variety of fruits, berries,
and seeds. The food was delivered daily at no costs to the participants during the study period.
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Table 4. One week of the Okinawan-based Nordic diet.
Breakfast
Porridge or sour milk with muesli, sandwich with cheese or ham, fruit
Morning Tea
Arranged individually
Lunch
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
French vegetable soup,
basil pesto, wholegrains
Apple compote, vanilla
yoghurt, Igelösa
wholegrain sprinkle
Salmon pudding, dill
and mustard yoghurt
sauce, cauliflower,
cabbage salad with
quinoa
Carrot and coconut soup,
red lentils and prawns,
wholegrains
Salmon with saffron
sauce, wholegrains,
ratatouille
Italian millet nuggets,
basil and sundried
tomato yoghurt sauce,
grilled vegetables
Sesame fried salmon, black
rice, sesame chili sauce,
broccoli and carrots
Mush room soup,
wholegrains, zucchini
bread
Afternoon Tea
Orange and almonds Pear and bean trufflewith taste of orange Apple and walnuts
Pear and bean truffle
with brandy flavoring Orange and almonds
Apple and a piece of dark
chocolate Pear and walnuts
Dinner
Sausage stroganoff, rice,
green peas
Aubergine pizza,
cabbage salad with
lentils, basil pesto
with yoghurt sauce
Grilled chicken, mustard
sauce, grilled vegetables
Chocolate cake, bilberry,
whipped cream
Beef stew, mixed
vegetables,
wholegrains
Pasta with minced
chicken-sauce
Potato burgers with feta
cheese and sundried
tomatoes, grilled vegetables,
tomato cream sauce
Cabbage pudding,
brown sauce,
lingonberries, grilled
vegetables
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The meal composition was close to a moderately low carbohydrate rich diet, one of four
recommended diets from the Swedish National Food Agency for patients with diabetes [46].
These recommendations were also consistent with international recommendations [47,48]. The diet
had a mean calorie intake of approximately 1800 kcal/day.
4.2. Medical Examination
All information on diabetes was collected from the available medical records of the study
participants. The information included data on serum HbA1c levels, duration of diabetes,
diabetic complications, and current insulin intake. Data on general health parameters were collected at
baseline and at two, and four weeks; including weight, body mass index (BMI), waist circumference,
blood pressure, and heartbeat. Fasting peripheral venous blood samples were drawn at baseline, and
at two and four weeks to study changes in serum hemoglobin, leucocytes, thrombocytes, long-term
sugar, sodium, potassium, creatinine, cholesterol, triglycerides, high- and low-density lipoproteins,
C-reactive protein, aspartate amino transferase (ASAT), alanine amino transferase (ALAT), HbA1c,
insulin, S-C-peptide, glucose and a selection of cytokines (see below).
4.3. Periodontal Examination
At baseline, at two weeks, and at four weeks, routine periodontal examinations were performed
by a periodontist (VWB). The following recordings were made: probing pocket depths (PPD), bleeding
on probing (BOP), and radiographic analysis of the extent of alveolar bone loss (only at the first visit).
PPDs at six sites per tooth (PCR-12, Hu-Friedy, Chicago, IL, USA). BOP was assessed 30 s after probing
at the sites of pocket probing. BOP was categorized as bleeding or no bleeding. A diagnosis of gingivitis
was declared if≥20% of assessed teeth presented with BOP but in the absence of radiographic evidence
of bone loss. A diagnosis of periodontitis was defined as the presence of BOP at ≥20%, and ≥2 sites
(not adjacent) with a PPD ≥5 mm, and with ≥10% of sites having radiographic evidence of alveolar
bone loss (≥4 mm between cement-enamel junction to alveolar bone) as assessed from panoramic
radiographs. Since periodontitis and alveolar bone loss will develop only gradually and over a longer
time span gingivitis was the parameter that best could identify improved oral health during the study
period. Consequently, this factor was the one that was recorded.
4.4. Cytokine Analysis
A commercially available panel of pro- and anti-inflammatory cytokines was assessed using
Luminex MagPix multi-analyte technology (Luminex, Austin, TX, USA). The cytokine analysis
was performed according to manufacturer’s instructions for the xMAP technology with multiplex
beads. Duplicate readings were made. Fluorescently labelled reporter molecules were measured and
cytokine concentrations calculated by Bio-Plex for the following cytokines; Basic FGF (basic fibroblast
growth factor), Eotaxin, GCSF (granulocyte colony-stimulating factor), IFN-γ (interferon gamma),
Interleukin (IL): IL1β (interleukin 1 beta), IL1ra (receptor antagonist), IL4, IL5, IL6, IL7, IL8, IL9, IL10,
IL12p70 (active heterodimer), IL13, IL17A, IP10 (interferon-inducible protein-10), MCP1 (monocyte
chemo-attractant protein-1), MIP1α (macrophage inflammatory protein 1 alpha), MIP1β (macrophage
inflammatory protein 1 beta), PDGF-BB (platelet-derived growth factor subunit B), TNF-α (tumor
necrosis factor-alpha), and VEGF (vascular endothelial growth factor). This set of immune markers
provides information on activation of the innate as well as the adaptive immune system including
both Th1 (cellular) and Th2 (humoral) immune responses.
4.5. Statistical Analysis
The statistical package SPSS 22 for Windows was used for all analyses. Wilcoxon signed-rank
test and independent t-test were used to assess medical and dental changes before and after intake of
study diet. A p-value below 0.05 was considered significant.
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